BPM Showcases DNlite® at MEDICA 2026
BPM Showcases DNlite® at MEDICA 2026:
Bridging Conventional Biomarker Gaps to Seize the "Golden Intervention Period"
Addressing the limitations of conventional testing · Certified under EU-IVDR Class C with approvals across 42+ countries · Opening 5 strategic partnering tracks in Düsseldorf
As chronic kidney disease (CKD) impacts more than 850 million individuals worldwide and diabetic kidney disease (DKD) continues to drive unsustainable dialysis expenses, BPM presents its first-in-class, EU-IVDR certified prognostic biomarker: DNlite® (uPTM-FetA ELISA). Designed to bridge the critical diagnostic limitations of conventional biomarkers, DNlite® identifies fast decliners during the crucial "Golden Intervention Period"—long before irreversible nephron scarring takes place. At MEDICA 2026, BPM is initiating discussions across five distinct global partnering tracks to reshape kidney disease prevention.
Commercial authorizations across Europe, the Middle East, Southeast Asia, and Latin America
Comprehensive intellectual property protecting uPTM-FetA biomarkers and detection methods
Certified under stringent European IVDR Class C diagnostic standards
Addresses UACR and eGFR limitations by stratifying progression risk during early microinjury
Diabetes remains the primary driver of end-stage renal disease (ESRD) and lifelong dialysis. However, current diagnostic standards suffer from fundamental limitations in detecting progressive risk:
- UACR (Albuminuria) Delay: Albuminuria indicates that structural damage to the glomerular filtration barrier has already occurred. Readings also fluctuate widely with exercise, infection, and blood pressure.
- eGFR Insensitivity: Often drops only after 30% to 50% of functional nephrons have been irreversibly lost, signaling established tubulointerstitial fibrosis.
- Lack of Risk Stratification: Standard tests cannot reliably distinguish rapid progressors from stable cohorts during early asymptomatic phases, resulting in missed windows for optimal therapy.
- Microenvironmental Cellular Precision: Quantifies urinary post-translationally modified Fetuin-A (uPTM-FetA) released during podocyte and tubular stress, providing dependable prognostic data when conventional tests remain inconclusive.
- Precise Risk Stratification: Distinguishes fast progressors from stable patients, enabling targeted, guideline-directed pharmacotherapy.
- Targeting the Golden Window: Directs timely treatment before permanent nephron scarring occurs, halting the slide toward costly dialysis.
The phase prior to persistent albuminuria represents the critical Golden Intervention Period. DNlite® bridges the shortcomings of standard tests during this window, allowing clinicians to intervene before irreversible structural damage occurs.
Complementing Conventional Tests
Addresses the diagnostic limitations of UACR and eGFR by detecting early microenvironmental tubular and podocyte stress before irreversible decline sets in.
Risk Stratification
Accurately differentiates fast decliners from stable patients, facilitating personalized care and eliminating costly, non-targeted overtreatment.
Timely Intervention
Provides actionable prognostic data to guide optimal timing for guideline-directed medical therapies (SGLT2i, GLP-1 RA, ns-MRA).
Non-invasive
Requires only a routine random urine sample. Avoids fasting blood draws or invasive biopsies, ensuring high patient adherence across primary and hospital care.
Robust Regulatory Moat with Dual Clinical Indications
DNlite® covers both Diabetic Kidney Disease (DKD) early prognosis and Kidney Transplant (KT) monitoring.
With GMP-compliant production and international clinical validation (including multi-cohort studies such as the landmark CREDENCE trial), BPM is primed to support swift commercial launches worldwide:
During MEDICA 2026, BPM's business development and scientific leadership will host partnering sessions at Hall 3 / Booth C26-1 across five focused collaboration tracks:
Global IVD Instrument Manufacturers
Co-development to adapt patented uPTM-FetA assays onto automated biochemistry or CLIA analyzers, enriching installed-base instruments with proprietary renal longevity test menus.
Medical Device & IVD Commercial Distributors
Leverage existing CE-IVDR and local registrations, backed by comprehensive manufacturer marketing and KOL literature, to fast-track hospital commercialization in Europe, Middle East, Asia, and Latin America.
Reference Laboratories & Checkup Centers
Rapid rollout through Laboratory Developed Tests (LDT) to offer high-value early screening packages for diabetic individuals, integrating with glycemic profiles for holistic cardio-renal evaluation.
Metabolic & Cardio-Renal Biopharma Sponsors
Patient enrichment in Phase II/III clinical trials to identify fast progressors, maximizing endpoint statistical power and collaborating on Companion Diagnostic (CDx) development.
Hospital Networks & Healthcare Systems
Establishing standardized "primary screening to nephrology intervention" clinical care loops, advancing Real-World Evidence (RWE) pilot programs to mitigate long-term dialysis burdens.
Schedule a 1-on-1 Partnering Meeting at Hall 3 / Booth C26-1
BPM's commercial leadership and scientific teams will be present throughout MEDICA 2026. Whether exploring diagnostic platform licensing, regional distribution, reference lab deployment, or clinical trial collaboration, we warmly invite you to schedule a meeting with us in Düsseldorf.
Related News
【Tai Yuen High-Tech Industrial Park】Engineers' Day Health Seminar
"Staying 'Online' with Your Health: Renal Risk in Tech Professionals × New Perspectives on Chronic Disease Management."
2026/05/27
Events
BPM & Partner Precision Diabetes to Showcase Landmark CREDENCE Data at ASN Kidney Week 2026
Selected Oral Presentation and Welcoming Global Partners at Booth A1011
2026/10/20
Events
BPM Debuts DNlite-IVD103 at the 57th ERA-EDTA Congress
Securing Early Wins in European and US Markets
2020/06/05
Events